SLC5A2 and diabetes mellitus: Is prescription co-payment associated with adherence to glucagon-like peptide-1 receptor agonist (GLP1-RA) or sodium-glucose cotransporter 2 inhibitor (SGLT2i) therapies in individuals with diabetes and/or heart failure?